Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27191816 | 0.83 | PRMT5 (0.35) | PRMT5WDR77HSP90AA1 | |
| SCHEMBL3151800 | 0.74 | BRAF (0.37) | PRMT5WDR77BRAFTP53GAA | |
| SCHEMBL21623709 | 0.74 | PRMT5 (0.32) | PRMT5WDR77BRAFPARP1TP53 | |
| SCHEMBL20380147 | 0.74 | BRAF (0.37) | PRMT5WDR77BRAFCDK2PARP1 | |
| SCHEMBL107328 | 0.74 | GAA (0.33) | PRMT5WDR77BRAFPARP1HRH3 | |
| SCHEMBL5496005 | 0.74 | MAPT (0.34) | PRMT5WDR77BRAFPARP1TP53 | |
| SCHEMBL3151793 | 0.74 | PRMT5 (0.32) | PRMT5WDR77BRAFPARP1TP53 | |
| SCHEMBL24345788 | 0.74 | PRMT5 (0.40) | PRMT5WDR77BRAF | |
| SCHEMBL13680777 | 0.71 | PRMT5 (0.32) | PRMT5WDR77BRAFTP53GAA | |
| SCHEMBL16324761 | 0.71 | TGFBR1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624041-B2 | Heterocyclic compound and use thereof | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2026-05-12 | — | — | US | disclosed |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20250011330-A1 | Imidazo[1,2- a]pyrazine and Imidazo[1,2- a]pyridine Based Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors | LEIDOS BIOMEDICAL RESEARCH INC. | 2025-01-09 | — | — | US | disclosed |
| US-12129257-B1 | Imidazo[1,2-a]pyrazine compounds as CK2 inhibitors | King Faisal University (SA) | 2024-10-29 | — | — | US | disclosed |
| US-20240317755-A1 | HETEROCYCLIC COMPOUND, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2024-09-26 | — | — | US | disclosed |
| CN-118063491-A | Imide catalyst auxiliary agent, polyimide film and preparation method | 中国科学院化学研究所 | 2024-05-24 | — | — | CN | disclosed |
| CN-114907408-B | Heterocyclic compound, intermediate thereof, preparation method and application thereof | 武汉朗来科技发展有限公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-4289846-A1 | HETEROCYCLIC COMPOUND, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289846-A1 | HETEROCYCLIC COMPOUND, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-7078405-B2 | Imidazo[1,2-b]pyridazine compound | EISAI CO., LTD. (JP) | 2006-07-18 | — | — | US | disclosed |
| WO-2005097052-A1 | KERATIN DYEING COMPOSITIONS BICYCLIC 5-6 HETEROAROMATIC DYEING COMPOUNDS WITH ONE RING NITROGEN JUNCTION | THE PROCTER & GAMBLE COMPANY (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050229333-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER & GAMBLE COMPANY, THE | 2005-10-20 | — | — | US | disclosed |
| US-20040082781-A1 | Bicyclic nitrogenous fused-ring compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| US-20030220342-A1 | Imidazo[1, 2-a] pyrazines for the treatment of irritable bowel syndrome | BAKTHAVATCHALAM RAJAGOPAL (US) | 2003-11-27 | — | — | US | disclosed |
| EP-1364952-A1 | BICYCLIC NITROGENOUS FUSED-RING COMPOUND | Eisai Co., Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
| US-6589952-B2 | Imidazo(1,2-a)pyrazines containing an aryl or heteroaryl group are useful as (corticotropin releasiang factor) CRF receptor antagonists in the treatment of various neurological and psychological disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-08 | — | — | US | disclosed |
| EP-1301511-A2 | IMIDAZO 1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Bristol-Myers Squibb Pharma Company (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20020049208-A1 | Imidazo[1,2-a]pyrazines for the treatment of neurological disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-25 | — | — | US | disclosed |
| WO-2002006286-A2 | IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220342-A1 | Imidazo[1, 2-a] pyrazines for the treatment of irritable bowel syndrome | SCN5A, HRH2, CHRNA5 | PRMT5 397/4885WDR77 1619/4885HSP90AA1 4192/4885 |
| US-12624041-B2 | Heterocyclic compound and use thereof | TRPC1, TRPC5, TRPC3 | PRMT5 2755/4885WDR77 1707/4885HSP90AA1 4457/4885 |
| US-20020049208-A1 | Imidazo[1,2-a]pyrazines for the treatment of neurological disorders | CRHR1, CRHR2, CRH | PRMT5 1392/4885WDR77 1930/4885HSP90AA1 1870/4885 |
| US-20250011330-A1 | Imidazo[1,2- a]pyrazine and Imidazo[1,2- a]pyridine Based Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors | TDP1, TDP2, TOP1 | PRMT5 529/4885WDR77 1565/4885HSP90AA1 472/4885 |
| US-12129257-B1 | Imidazo[1,2-a]pyrazine compounds as CK2 inhibitors | CSNK2A1, CSNK2A2, CSNK1A1 | PRMT5 3893/4885WDR77 2628/4885HSP90AA1 673/4885 |
| US-20050229333-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | KRT18, CKMT1A; CKMT1B, JUP | PRMT5 472/4885WDR77 3585/4885HSP90AA1 2521/4885 |
| US-20040082781-A1 | Bicyclic nitrogenous fused-ring compound | CRHR1, CRH, CRHR2 | PRMT5 650/4885WDR77 2547/4885HSP90AA1 4496/4885 |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | KRAS, NRAS, HRAS | PRMT5 422/4885WDR77 1136/4885HSP90AA1 3600/4885 |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | PRMT5 1694/4885WDR77 1749/4885HSP90AA1 3958/4885 |
| US-20240317755-A1 | HETEROCYCLIC COMPOUND, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | CYP4A11, CYP4F11, CYP51A1 | PRMT5 3168/4885WDR77 1078/4885HSP90AA1 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.